Eurofins: Forget Revenue Growth, Watch The Margins

Impact · against what's priced in

Eurofins shows a shift in value drivers where margin expansion and operational leverage offset stagnant organic growth. The profitability beat and strategic portfolio rotation provide a positive catalyst for the stock price.

ERFSF+0.50

No priced-in read yet

In context

The adjusted EBITDA margin of 23.7% exceeded expectations, and the acquisition of Element's Life Sciences alongside the sale of MET Labs optimizes the core portfolio.

Read from the article alone

• organic growth▲250%
• earnings▲17%
• m and a
• ERFSF
• capital rotation
• ebitda
• laboratory services
• margins